The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with obesity.
Key Takeaways Eli Lilly's Zepbound can be covered by Medicare Part D plans after the FDA approved the drug as a treatment for ...
Adam Maeder, an analyst from Piper Sandler, has initiated a new Hold rating on Resmed (RMD).Stay Ahead of the Market:Discover outperforming ...
El Lilly’s blockbuster weight-loss drug Zepbound is now eligible for coverage under Medicare prescription drug plans, when ...
Metabolic medicines dominated life sciences headlines in 2024, a trend expected to continue into the new year. Other things ...
The government-funded insurance plan will now pay for the drug for patients with obstructive sleep apnea, a condition that ...
Zepbound is not covered by Medicare or many other insurance plans as a treatment for weight loss. The injectable treatment ...